Real-World Evidence of SUL-DUR on Special Populations with CRAB Infection RFP Grant

Real-World Evidence of SUL-DUR on Special Populations with CRAB Infection RFP Grant

Status: ACTIVE
Funder: Pfizer, Inc.
Amount: Up to US $27,000
Last Updated: April 02, 2026

Summary

Overview

Note: Requesting organization must be legally able to receive award funding directly from Pfizer Investment Co., Ltd.. We strongly recommend that applicants confirm this with their organization or institution prior to submitting an application. Grants awarded to organizations that are subsequently found to be unable to accept funding directly from Pfizer Investment Co., Ltd. may be subject to rescission. About Pfizer Grants Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies. Real-World Evidence of SUL-DUR on Special Populations with CRAB Infection This competitive program aims to evaluate the real-world evidence on effectiveness and safety of Sulbactam-Durlobactam (SUL-DUR), as well as the influence of SUL-DUR treatment timing on clinical outcomes in special adult populations. The study will focus on patients with suspected or confirmed carbapenem-resistant Acinetobacter baumannii (CRAB) infection in China. Special populations include critically ill patients; recipients with solid organ transplant (SOT); and patients with hematological diseases. Project Types and Area of Interest Potential applicants are requested to submit research proposals to study realworld evidence on effectiveness, safety of SUL-DUR, and influence of SULDUR treatment timing on clinical outcomes for CRAB infections in special adult populations. Critically ill patientsSOT patientsPatients with hematological diseases

Eligibility

We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's website.